# A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

> **NCT05033132** · PHASE2 · WITHDRAWN · sponsor: **Agenus Inc.**

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Balstilimab
- **DRUG:** Balstilimab + Zalifrelimab

## Key facts

- **NCT ID:** NCT05033132
- **Lead sponsor:** Agenus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never initiated.
- **Last updated:** 2024-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05033132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05033132, "A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05033132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*